The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical ...

Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create ...

Reduction-in-force notices went out Tuesday morning to employees across HHS. At FDA, OND director Peter Stein is departing as ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Teams working on device communications and policy were cut from the agency on Tuesday, according to multiple FDA workers.